Compare YPF & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YPF | EXEL |
|---|---|---|
| Founded | 1977 | 1994 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4B | 17.8B |
| IPO Year | 1995 | 2000 |
| Metric | YPF | EXEL |
|---|---|---|
| Price | $37.18 | $69.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 17 |
| Target Price | $60.78 | ★ $61.57 |
| AVG Volume (30 Days) | 1.3M | ★ 2.5M |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | N/A | ★ 2.46 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | $58.16 | $10.14 |
| Revenue Next Year | N/A | $12.56 |
| P/E Ratio | ★ N/A | $28.89 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.74 | $39.71 |
| 52 Week High | $57.87 | $73.69 |
| Indicator | YPF | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 21.37 | 62.76 |
| Support Level | $36.04 | $55.28 |
| Resistance Level | $39.96 | N/A |
| Average True Range (ATR) | 2.02 | 2.45 |
| MACD | -1.06 | 0.04 |
| Stochastic Oscillator | 4.73 | 61.25 |
YPF SA is an Argentina-based integrated oil and gas company. The company operates through four business segments: Upstream, Midstream and Downstream, LNG and Integrated Gas, and New Energies. The Upstream segment focuses on the exploration and production of crude oil and natural gas. The Midstream and Downstream segment includes refining, transportation, and commercialization of crude oil, refined, and petrochemical products. The LNG and Integrated Gas segment is involved in natural gas transportation, processing, storage, and commercialization. The New Energies segment focuses on energy transition initiatives, including natural gas distribution, power generation, renewable energy, and related technology development. It generates majority of revenue from Midstream and Downstream segment.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.